Meeting
2020 ASCO Virtual Scientific Program
Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
Authors
Geraldine Helen O'Sullivan Coyne
Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
Geraldine Helen O'Sullivan Coyne , Andrea M. Gross , Eva Dombi , Cecilia Tibery , Amanda Carbonell , Naoko Takebe , Joanne Derdak , Dominique Pichard , Apurva K. Srivastava , William Herrick , Ralph E. Parchment , Staci Martin , Pamela Wolters , Patricia Whitcomb , Lawrence Rubinstein , James H. Doroshow , Alice P. Chen , Brigitte C. Widemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02407405
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3612)
DOI
10.1200/JCO.2020.38.15_suppl.3612
Abstract #
3612
Poster Bd #
342
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
First Author: Diana Bradford
Poster
2014 ASCO Annual Meeting
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
First Author: Brigitte C. Widemann
Poster
2021 ASCO Annual Meeting
Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.
First Author: Katy K. Tsai
Poster
2024 ASCO Annual Meeting
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.
First Author: Graeme Currie